Professionals 876 results
Capabilities 91 results
Practice Area
Region
Practice Area
Experience 377 results
Experience
|December 11, 2025
Winston Takes the Checkered Flag After “Massive Win” Settlement
Experience
|November 19, 2025
Blockfusion Enters into Business Combination with Blue Acquisition Corp.
Experience
|October 27, 2025
Winston Advised GenNx360 Capital Partners in its sale of Aero 3, Inc.
Insights & News 7,165 results
Seminar/CLE
|January 22, 2026
14th ITA-IEL-ICC Joint Conference on International Energy Arbitration – Houston
Capital Markets & Securities Law Watch
|December 31, 2025
|5 Min Read
Section 16 Obligations Expand to Apply to Foreign Private Issuers
On December 18, 2025, as part of the National Defense Authorization Act for fiscal year 2026, the Holding Foreign Insiders Accountable Act (HFIAA) was signed into law. The HFIAA amends Section 16(a) of the Securities Exchange Act of 1934 to require directors and executive officers of foreign private issuers with a class of equity securities registered under Section 12 of the Exchange Act to comply with the same insider reporting rules that apply to U.S. domestic issuers. Beginning in March 2026, covered FPI insiders must publicly disclose their equity ownership and transactions on the same forms used by U.S. issuers—Forms 3, 4, and 5.
Client Alert
|December 31, 2025
|4 Min Read
New York FAIR Business Practices Act Bolsters State’s Consumer Protection Framework
Not quite a year after the Consumer Financial Protection Bureau (CFPB) issued its January 2025 report urging states to strengthen state-level consumer protections, New York enacted the Fostering Affordability and Integrity through Reasonable (FAIR) Business Practices Act into law. The FAIR Act amends New York’s general business law to prohibit unfair and abusive business acts and practices beyond deceptive conduct.
Other Results 213 results
Law Glossary
What Is Consumer Marketing Law?
Law Glossary
What Is Consumer Targeting Law?
Law Glossary
What Statutes and Regulations Govern the Approval and Marketing of Biosimilars?


